You can buy or sell BioDelivery and other stocks, options, ETFs, and crypto commission-free!
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. Read More The company was founded in 1997 and is headquartered in Raleigh, NC.
Raleigh, North Carolina
52 Week High
52 Week Low
Yahoo FinanceMar 15
BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
BioDelivery Sciences International, Inc. BDSI reported loss of 10 cents per share for fourth-quarter 2018, meeting the Zacks Consensus Estimate. In the year-ago quarter, the company had recorded a loss of 29 cents per share. Revenues were $18 million in the reported quarter, up 44.1% from the year-ago period and 27.4% sequentially. The increase in sales was mainly driven by strong demand for Belbuca, which exceeded the company’s expectations. The top line beat the Zacks Consensus Estimate of $16.15 million...
Seeking AlphaMar 15
BioDelivery Sciences International, Inc.'s (BDSI) CEO Herm Cukier on Q4 2018 Results - Earnings Call Transcript
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Q4 2018 Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants Herm Cukier - Chief Executive Officer Scott Plesha - President and Chief Commercial Officer Thomas Smith - Chief Medical Officer Terry Coelho - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Esther Hong - Janney Capital Markets Tim Lugo - William Blair Matt Kaplan - Ladendburg Thalmann Oren Livnat - HC Wainwright Operator ...
-$0.10 per share
-$0.10 per share